Fig. 1: PARIS® assay workflow including organoid generation from the fresh surgical specimen, genomic characterization, and report generation. | npj Precision Oncology

Fig. 1: PARIS® assay workflow including organoid generation from the fresh surgical specimen, genomic characterization, and report generation.

From: Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Fig. 1

a Schematic of the clinical integration of the PARIS® drug sensitivity assay. WES: whole exome sequencing. Created with BioRender.com. b Brightfield photomicrograph of the patient’s cultured tumor organoids. Scale bar = 50 μm. c Mutational landscape of the primary tumor from Foundation One and all confirmed in tumor-derived organoids. The Foundation One (FO) report only reported mutations with >0.05 variant allele frequency (VAF) but did not report the actual value for each gene. ND not detected. d Table of top-scoring drugs in green from the PARIS® assay. In red are classes of drugs that the patient took prior to the PARIS® test. The results indicating oxaliplatin, taxanes, and ER targeting drugs showed no to borderline (dotted line) sensitivity.

Back to article page